Aventis Lantus Phase IIIb Trial To Compare Nocturnal Hypoglycemia Rates
Aventis is conducting a Phase IIIb trial to compare the incidence of nocturnal hypoglycemia with its insulin glargine product Lantus and NPH human insulin (Lilly's Humulin or Novo Nordisk's Novolin) in patients with type 2 diabetes.
You may also be interested in...
Aventis Pharma is targeting a fourth quarter NDA filing for its Insuman recombinant human insulin family after undergoing some changes in the manufacturing process of the compound.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials